# Healthcare deal-making and drug wins line up — buy Surgery Partners below the takeover price and ride AstraZeneca's trial boost

_AI-generated trading idea · BULLISH · AZN, SGR_

> Canonical page: https://commonquant.ai/research/for-you/healthcare-deal-making-and-drug-wins-line-up-buy-surgery-par--8159305f-1ff4-5ab0-8b59-0d56821a967c

Surgery Partners trading below the reported $20-a-share takeover valuation offers a classic buyout spread: if the deal closes, the stock converges to the offer price, and even a modest discount leaves room for gain. AstraZeneca's positive late-stage survival data is the kind of result that historically drives sustained buying in a large pharma name rather than a one-day pop. Together, the two stories show deal-making appetite and drug-pipeline strength hitting healthcare at once — a sector where money can rotate while AI and tech wobble. A paired long captures both the merger-arbitrage carry and the pharma catalyst.

## Idea

Surgery Partners trading below the reported $20-a-share takeover valuation offers a classic buyout spread: if the deal closes, the stock converges to the offer price, and even a modest discount leaves room for gain. AstraZeneca's positive late-stage survival data is the kind of result that historically drives sustained buying in a large pharma name rather than a one-day pop. Together, the two stories show deal-making appetite and drug-pipeline strength hitting healthcare at once — a sector where money can rotate while AI and tech wobble. A paired long captures both the merger-arbitrage carry and the pharma catalyst.

## Advanced Analysis

### Verdict: strong AZN fundamentals, but the SGR spread is unpriceable and the entry is broken — wait

Our stance is wait, on a three-month horizon, because the idea pairs one well-supported business with one that cannot yet be evaluated: AstraZeneca's fundamentals are strong, but the Surgery Partners takeover spread rests on the idea's own $20-a-share claim with no confirmed terms and no SGR price data to measure any discount. The strongest point for the thesis is AZN's FY2025 result — revenue up 8.6% to $58.7B, net income up 45.3% to $10.2B, and free cash flow up 18.4% to $11.8B — which supports the pharma catalyst leg, reinforced by the Reuters-reported late-stage survival data from October 25, 2026. The strongest point against is that the entry rule set is internally contradictory (a close both below and above the 50-day average) and that AZN, at $171.49 versus its 50-day average of $162.89 with momentum at 66.6, is extended relative to any pullback entry; additionally, AZN cut its latest annual payout roughly 31% versus 2025's $3.13 per share. A merger spread you cannot price is not a trade, so no position is warranted until SGR's deal terms and price series exist. The verdict flips if a confirmed offer price, timeline, and tradeable SGR quote appear alongside a coherent AZN pullback entry near support with cooling momentum. No robust parameter setup was established because AZN's historical evaluation could not be run on mismatched price bases.

#### Conviction score breakdown

Composite score computed by the server from the applicable evidence-tier dimensions.

| Measure | Value |
| --- | ---: |
| Thesis support | 55/100 |
| Trade readiness | 20/100 |
| Risk quality | 35/100 |
| Trigger proximity | 25/100 |
| Fundamentals trend | 75/100 |
| Score | 42/100 |
| Composite Score | 42/100 |
| Evidence Tier | rules\_not\_triggered |

#### Decision scenarios

Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts.

| Measure | Value |
| --- | ---: |
| Evidence Tier | rules\_not\_triggered |

### Trade now: the entry rules cannot fire, and the spread leg has no live data

Wait — and, more precisely, this setup cannot be entered as written. The business thesis is easy to separate from the trigger: AstraZeneca's fundamentals support the idea's bullish pharma leg, with FY2025 revenue up 8.6% to $58.7B, net income up 45.3% to $10.2B, and free cash flow up 18.4% to $11.8B, plus a gross margin of 81.9%. But the Surgery Partners takeover-spread leg rests entirely on the idea's own $20-a-share claim — no offer date, terms, or company disclosure is supplied — and SGR has no price history in our data at all, so the discount cannot be measured. A merger spread you cannot price is not a trade.

The technical entry is also broken rather than merely distant. The compiled rules require AZN's daily close to be both below and above the 50-day average at the same time — a contradiction that can never trigger. The research author flagged this and requested a bounded optimization search, but no robust alternative setup was established: the historical evaluation could not be run because AZN's raw and adjusted price series use different bases, so no tested result stands behind any parameterization. Treat this as a watch-list idea, not an actionable signal.

If a corrected, thesis-consistent pullback setup is adopted, it would look like a buy near dynamic support with momentum cooling: AZN's last close was $171.49 (as of the October 25, 2026 daily bar), about 3.2% above its 50-day average of $162.89, and the RSI momentum reading — a 0-100 gauge where lower readings indicate cooling buying pressure — sits at 66.6, well above the 45-50 band the rules want. The downside that matters for a long is the 2% stop in the rules; AZN's 25.7% maximum drawdown over the two-year lookback is a reminder that a fixed small stop can be clipped quickly in a name with this volatility (annualized around 27-29%). Concretely, "wait" means: no position until a coherent, internally consistent entry rule set is published and AZN's price and momentum fall back toward the pullback zone the thesis describes.

#### AZN price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | AZN |
| Timeframe | 1d |

### Placeholder title

Placeholder body.

#### AZN Free cash flow

Free cash flow trend from CommonQuant fundamentals/XBRL data; +489.4% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2015-12-31 | $1996000000 |
| 2016-12-31 | $2699000000 |
| 2017-12-31 | $2252000000 |
| 2018-12-31 | $1575000000 |
| 2019-12-31 | $1990000000 |
| 2020-12-31 | $3838000000 |
| 2021-12-31 | $4872000000 |
| 2022-12-31 | $8717000000 |
| 2023-12-31 | $8984000000 |
| 2024-12-31 | $9937000000 |
| 2025-12-31 | $11765000000 |
| Latest Value | $11765000000 |
| Change Pct | $489.42885771543087 |
| Ticker | AZN |
| Timeframe | reported periods |

#### AZN sector percentile check

Ranks AZN against 1243 companies in its sector using CommonQuant fundamentals.

| Measure | Value |
| --- | ---: |
| Free cash flow | \99.71842316975061th percentile |
| Operating margin | \92.57332071901608th percentile |
| Return on equity | \84.20229405630866th percentile |
| Gross margin | \78.52011494252874th percentile |
| Ticker | AZN |
| Sector | Health Care |
| Peer Count | 1243 |

### Placeholder title

Placeholder body.

#### Rule trigger diagnostic

The rule set was evaluated against real market bars but did not open an entry; use the watch triggers as the actionable read.

| Measure | Value |
| --- | ---: |
| Bars evaluated | 54 count |
| Entries | 0 count |

#### AZN Return on equity

Return on equity trend from CommonQuant fundamentals/XBRL data; -98.1% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2015-12-31 | \0.1527852893455922% |
| 2016-12-31 | \0.23555944526726807% |
| 2017-06-30 | \0.03493737640079103% |
| 2017-12-31 | \0.20060160427807486% |
| 2018-06-30 | \0.0276789244760775% |
| 2018-12-31 | \0.17284247674045558% |
| 2019-06-30 | \0.009595512252731031% |
| 2019-12-31 | \0.1016987887559991% |
| 2020-06-30 | \0.06177984800196127% |
| 2020-12-31 | \0.20458327998975803% |
| 2021-06-30 | \0.03508548099004848% |
| 2021-12-31 | \0.002852195171641031% |
| Latest Value | \0.002852195171641031% |
| Change Pct | \-98.13320039916309% |
| Ticker | AZN |
| Timeframe | reported periods |

#### AZN Operating margin

Operating margin trend from CommonQuant fundamentals/XBRL data; -82.6% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2015-12-31 | \0.16650477578112352% |
| 2016-12-31 | \0.2299357380740185% |
| 2017-06-30 | \0.18724696356275303% |
| 2017-12-31 | \0.1824632790789996% |
| 2018-06-30 | \0.15168986083499006% |
| 2018-12-31 | \0.16091025701933584% |
| 2019-06-30 | \0.08621895767750962% |
| 2019-12-31 | \0.12408232548270741% |
| 2020-06-30 | \0.21230158730158732% |
| 2020-12-31 | \0.19938200077249904% |
| 2021-06-30 | \0.1400870105655687% |
| 2021-12-31 | \0.028899044908458994% |
| Latest Value | \0.028899044908458994% |
| Change Pct | \-82.64371410796781% |
| Ticker | AZN |
| Timeframe | reported periods |

### Company context

\#\#\# AZN \*\*Ownership and insiders.\*\* For the period ending September 30, 2026, 139 reporting holders were counted, holding roughly 9.24M reported shares. Insider filings indicate net open-market selling, netting about -$2.21M. Coverage: Provisional. \*\*Management.\*\* Mr. Pascal Claude Roland Soriot, D.V.M., M.B.A. is identified as chief executive. He is listed as CEO & Executive Director, with reported total pay of $8.2M for fiscal 2025. Source: \[Yahoo Finance quoteSummary\](https://finance.yahoo.com/quote/AZN/profile), retrieved October 25, 2026. \*\*Dividends.\*\* Trailing twelve-month distributions total $2.153 per share; the latest observed ex-date was February 19, 2026, at $2.153 per share. The latest annual comparison is -31.2%. Source: \[Yahoo Finance corporate actions\](https://finance.yahoo.com/quote/AZN/history?filter=div),…

### Scores

- **Conviction score breakdown:** 42
- **Thesis support:** 55
- **Trade readiness:** 20
- **Risk quality:** 35
- **Trigger proximity:** 25
- **Fundamentals trend:** 75

### Watch items

- **SGR — Discount to reported $20 takeover valuation**
- **AZN — Close vs EMA (50)**
- **AZN — RSI (14)**
- **AZN — Insider net open-market activity**
- **AZN — Unrealized loss on any future position**

## Key details

- Symbols: AZN, SGR
- Timeframes: 1d
- Tags: \#canonical-demand, \#cluster-version:1, \#direction:bullish, \#entity-kind:instrument, \#entity:AZN, \#entity:SGR, \#horizon:unspecified, \#intent:research, \#symbol:AZN, \#symbol:SGR

## Community

- Upvotes: 0
- Views: 0
- Copies: 0
- Cosigns: 0

## News sources

- [Bon Secours Nears $6B Takeover of Surgery Partners: FT](https://www.bloomberg.com/news/articles/2026-10-25/bon-secours-nears-6b-takeover-of-surgery-partners-ft) — Bloomberg
- [AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds - Reuters](https://news.google.com/rss/articles/CBMixwFBVV95cUxPQWE1d0RDaXR0T1dzS004NG1pSU9IVjEtNGF5VEVlY3hoVDh2eVYyLUZMZl93ckdRbnpkOVgyXzFXYzlyRmdZbWtaWnJXS2tuUWtNN2R6LXI3STllOWtwX2RVUTc2RUVPTmZhYlRsYWIwcWppeDVHdkRtUlVpRjB1QlVYUTNXSks3SDh4bGJsUkhjN2c0ZkpyNWlOcW0xbWFWSzZmQmpOYXBEYW5SY01CdWVjSEZMVXBtNUpRZjFLb0Z4T1ZCWmRB?oc=5) — Reuters

## Related

- [AZN trade ideas](https://commonquant.ai/markets/azn)
- [SGR trade ideas](https://commonquant.ai/markets/sgr)
- [Latest market news](https://commonquant.ai/news)

## About CommonQuant Research

Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (over a timeframe-dependent historical window with walk-forward tuning) and stress-tested before they can go live, then monitored against the news hourly while they run.